Redx Pharma competitors

Redx Pharma's competitors include Otonomy, Biogen, MyoKardia and Athersys
Add company...
Redx Pharma
Redx Pharma is a leading UK biotech developing new drugs to treat cancer, infectious diseases and a range of other health issues.
Otonomy
Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.
Biogen
Biogen develops, markets and manufactures therapies for people living with serious neurological, autoimmune and rare diseases.
MyoKardia
MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
Athersys
Athersys, a biopharmaceutical company, discovers and develops therapeutic products for the treatment of several disease indications.
Founding Date
Founding Date
2010
Founding Date
2008
Founding Date
1978
Founding Date
2012
Founding Date
1995
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Liverpool, GB HQ
Cheshire East, GB
Locations
San Diego, US HQ
Locations
Cambridge, US HQ
Locations
South San Francisco, US HQ
Locations
Cleveland, US HQ
Canton, US
Employees
Employees
145
Employees
139
Employees
7,3001% decrease
Employees
1024% increase
Employees
60
Valuation ($)
Valuation ($)
39.2 m
Valuation ($)
95 m
Valuation ($)
69.1 b
Valuation ($)
2.3 b
Valuation ($)
274.4 m
Facebook likes
Facebook likes
N/A
Facebook likes
1.1 k
Facebook likes
3.1 k
Facebook likes
N/A
Facebook likes
475
Twitter followers
Twitter followers
995
Twitter followers
267
Twitter followers
19.4 k
Twitter followers
387
Twitter followers
953

Financial

Revenue (est.)
Revenue (est.)
£30.5m (FY, 2017)
Revenue (est.)
$1.2m (FY, 2017)
Revenue (est.)
$11.4b (FY, 2016)
Revenue (est.)
$22.5m (FY, 2017)
Revenue (est.)
$3.7m (FY, 2017)
Net income
Net income
£1.5m (FY, 2017)
Net income
($90.1m) (FY, 2017)
Net income
$3.7b (FY, 2016)
Net income
($46m) (FY, 2017)
Net income
N/A

Operating

Patents (US)
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
4 (FY, 2017)
Patents (US)
21 (FY, 2016)
Patents Issued
Patents Issued
N/A
Patents Issued
88 (FY, 2016)
Patents Issued
N/A
Patents Issued
N/A
Patents Issued
200 (FY, 2016)
Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
1 (FY, 2016)
Phase I Trials Products
4 (FY, 2016)
Phase I Trials Products
2 (FY, 2017)
Phase I Trials Products
N/A
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
2 (FY, 2016)
Phase II Trials Products
10 (FY, 2016)
Phase II Trials Products
1 (FY, 2017)
Phase II Trials Products
N/A
Phase III Trials Products
Phase III Trials Products
N/A
Phase III Trials Products
2 (FY, 2016)
Phase III Trials Products
2 (FY, 2016)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Preclinical Phase Products
Preclinical Phase Products
N/A
Preclinical Phase Products
1 (FY, 2016)
Preclinical Phase Products
N/A
Preclinical Phase Products
3 (FY, 2017)
Preclinical Phase Products
N/A

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
$ 153.4m
Total funding raised
N/A
Total funding raised
$ 98m
Total funding raised
$ 9m
For sources of this data, please see the company profileDownload Excel

View company profiles

Otonomy
HQ
San Diego, US
Employees
139

Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.

View company
Biogen
HQ
Cambridge, US
Employees
7,300↓ 1% decrease

Biogen develops, markets and manufactures therapies for people living with serious neurological, autoimmune and rare diseases.

View company
MyoKardia
HQ
South San Francisco, US
Employees
102↑ 4% increase

MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.

View company
Athersys
HQ
Cleveland, US
Employees
60

Athersys, a biopharmaceutical company, discovers and develops therapeutic products for the treatment of several disease indications.

View company